August 7, 2023

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

ACTIVATIONS

GASTROINTESTINAL

NRG-GI007: Reopening to the expansion cohort and Protocol Amendments 5-6. See Study Memorandum dated August 7, 2023. An updated drug ordering form is also available. Protocol and ICF posted on CTSU; all other documents posted on NRG).

CLOSURES & SUSPENSIONS

GENITOURINARY

NRG-GU007: Temporary Closure Notice, dated August 1, 2023 (posted on CTSU).

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BRAIN

NRG-BN009 - Sites in Canada only: The NOL and additional forms for amendment 1 are posted on CTSU. Please complete and submit the CTSI, Protocol signature page via the Regulatory submission portal.

NRG-BN009: The Spanish-translated consent form for Amendment 1 and CIRB approval of the form are available on the CTSU website.

3. BREAST

NRG-BR007/DEBRA: Updated QOL Packet (dated July 28, 2023). Posted under the CIRB tab on the NRG-BR007 page on CTSU).

NSABP B-51/RTOG 1304: Call for submission of data and supporting documentation. Please see the memorandum, dated June 27, 2023, posted on CTSU for additional information.

NRG-BR008/HERO: Study overview webinars are being held via Microsoft Teams on August 21st at 11am EDT and August 23rd at 3pm ET. Please see the memorandum, dated July 17, 2023, (posted on CTSU) or the July 26^th NRG Special Broadcast for details and how to register for one of the sessions. Please note: Google Chrome is the preferred browser to register for the webinars.

4. CANCER CONTROL & PREVENTION

NRG-CC005/FORTE: August 2023 FORTE Newsletter (posted on CTSU)

5. GASTROINTESTINAL

NRG-GI002: Call for submission of data and supporting documentation. Please refer to the memorandum, dated July 10, 2023, posted on the CTSU website for additional information.

NRG-GI004/S1610/COMMIT: Study Overview Webinar (posted on NRG Oncology under the Documents & Materials tab).

6. GENITOURINARY

NRG-GU009: The Spanish-translated consent form for Amendment 3 and CIRB approval of the form are available on the CTSU website.

7. GYNECOLOGIC

GOG-0210: Reminder: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

Printing Biospecimen Transmittal PDFs on GYN Trials

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

8. HEAD & NECK

NRG-HN008

Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

9. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday August 9, 2023.

DRUG SAFETY UPDATES

Drug Safety updates have been issued for the following studies:

HDC Symposium recording available

The recording of the NRG Health Disparities Symposium, Social Determinants of Cancer Care ~ Lessons Learned and Future Directions (held June 30, 2023) is now posted under the NRG Health Disparities Committee page on the NRG Oncology website.

• To view the recording: Click here (login required)
• To view the informational flyer about the program: Click here

New Process for NRG NCORP Pilot Grant Applications

NRG NCORP committee leaders will host a pilot grant workshop during the NRG winter meeting, February 15-17, 2024. The goal of the workshop is to prepare investigators and researchers to develop committee aim-aligned NCORP pilot projects that would potentially lead to a larger NCORP concept.

• An informational webinar to introduce the new process will be held on September 11, 2023. Registration is required (click here to register)
• The LOI process is a prerequisite of the pilot grant application submission for 2024. Interested investigators are required to submit a two-page LOI form, due November 3, 2023 (LOI form located here).
• The full request for funding application (RFA) for NCORP pilot projects will be released in spring 2024. While workshop selection and enrollment does not guarantee pilot funding, the activities are designed to facilitate successful submissions.
• NCORP committee chairs will review LOIs and select those best aligned with the committee goals, NCORP priorities, and deemed most feasible for future Phase II – III NCORP concepts.
• Selected investigators will be invited to attend a workshop during the winter NRG meeting.



For more information, please visit the NRG NCORP webpage.

NRG Oncology is pleased to report the scientific articles that appeared during the previous week. This publications report includes the link to these articles.

JOURNAL ARTICLES

Kim IA, Winter KA, Sperduto PW, Santos JFL, Peereboom DM, Ogunleye T, Boulter D, Fritz JM, Cho KH, Shin KH, Zoberi I, Choi S, Palmer JD, Liem B, Kim YB, Anderson BM, Thakrar AW, Muanza TM, Kim MM, Choi DH, Mehta MP, White JR. Concurrent lapatinib with brain radiotherapy in HER2+ breast cancer patients with brain metastases - NRG ONCOLOGY-KROG/ RTOG 1119 phase II randomized trial. Int J Radiat Oncol Biol Phys. 2023 Jul 26:S0360-3016(23)07681-2. doi: 10.1016/j.ijrobp.2023.07.019. Epub ahead of print. PMID: 37506981. Read more.

Konski A, Deshmukh S, Klopp AH, Yeung AR, Westin SN, Thompson JS, Doncals DE, Cantuaria GHC, D'Souza DP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203. Gynecol Oncol. 2023 Aug;175:176-181. doi: 10.1016/j.ygyno.2023.05.074. Epub 2023 Jun 30. PMID: 37393743. Read more.

This article is a republication (JCO.2005.04.7985) as part of the JCO 40^th Anniversary Flashback Series:

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023 Jul 10;41(20):3565-3575. doi: 10.1200/JCO.22.02570. PMID: 37406456. Read more.

Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 Aug;84(2):156-163. doi: 10.1016/j.eururo.2023.04.024. Epub 2023 May 12. PMID: 37179241. Read more.

ACCEPTED ABSTRACTS

Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJ, Aldape KD, Wefel J, Gondi V, Gutierrez AN, Manasawala M, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil E, Lukas RV, Goldlust SA, Snuderl M, Dignam JJ, Won M, Movsas B, Mehta MP. NRG Oncology Study BN007: Randomized phase II/III trial of ipilimiumab (Ipi) plus nivolumab (Nivo) vs. temozolomide (TMZ) in MGMT-unmethylated (uMGMT) newly diagnosed glioblastoma (nGBM). EANO (European Association of Neuro-Oncology). EANO Best Oral Presentation Award for Clinical Research. Abstract # PL02.3.A. Plenary Session (PL02) Award Winning Abstracts Date/Time: Sep 23, 10am-11am ET.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Society for Radiation Oncology (ASTRO); Oct 1-4, 2023; Chicago, IL



International Society for Quality-of-Life Research (ISOQOL); Oct 18-21, 2023; Calgary, AB Canada

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Society of Clinical Oncology (ASCO) GI; Jan 18-20, 2024; San Francisco, CA; due to publications committee Aug 31, 2023; meeting submission deadline Sep 19, 2023, 11:59pm ET; LBA Oct 19, 2023, NOON ET

American Society of Clinical Oncology (ASCO) GU; Feb 16-18, 2023; San Francisco, CA; due to publications committee Sep 6, 2023; meeting submission deadline Sep 26, 2023, 11:59pm ET; LBA Oct 26, 2023, NOON ET

European Society of Gynaecological Oncology (ESGO); Sep 28-Oct 1, 2023; Istanbul, Turkey; LBA Aug 7, 2023

European Society for Medical Oncology (ESMO) Congress; Oct 20-24, 2023; Madrid, Spain; LBA Sep 14, 2023, 9pm CEST

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2023; Seoul, South Korea; Abstract & Film; TiP LBA, Aug 21, 2023

San Antonio Breast Cancer Symposium (SABCS); Dec 5-9, 2023; LBA Sep 30, 2023, 11:59pm CT

Society for NeuroOncology (SNO); Nov 15-19, 2023; Vancouver, Canada; LBA Sep 4, 2023, 5pm ET